These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 33653729)
1. Risk of DKA with SGLT2 inhibitors. Drug Ther Bull; 2021 May; 59(5):69. PubMed ID: 33653729 [No Abstract] [Full Text] [Related]
2. In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors. Liakos A; Tsapas A; Bekiari E Ann Intern Med; 2020 Dec; 173(12):JC70. PubMed ID: 33316195 [TBL] [Abstract][Full Text] [Related]
3. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature. Diaz-Ramos A; Eilbert W; Marquez D Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052 [TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis complicating the perioperative management of a patient with type 2 diabetes mellitus (T2DM) and Fournier's gangrene: A case report. Lindsay PJ; Gibson LE; Bittner EA; Berg S; Chang MG Int J Surg Case Rep; 2020; 77():463-466. PubMed ID: 33395826 [TBL] [Abstract][Full Text] [Related]
5. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. Burke KR; Schumacher CA; Harpe SE Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088 [TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors. Jeon JY; Kim SK; Kim KS; Song SO; Yun JS; Kim BY; Kim CH; Park SO; Hong S; Seo DH; Seo JA; Noh JH; Kim DJ; Diabetes Metab; 2019 Oct; 45(5):453-457. PubMed ID: 30639566 [TBL] [Abstract][Full Text] [Related]
7. Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin. Kelmenson DA; Burr K; Azhar Y; Reynolds P; Baker CA; Rasouli N J Investig Med High Impact Case Rep; 2017; 5(2):2324709617712736. PubMed ID: 28634592 [TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674 [TBL] [Abstract][Full Text] [Related]
10. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis. Hampp C; Swain RS; Horgan C; Dee E; Qiang Y; Dutcher SK; Petrone A; Chen Tilney R; Maro JC; Panozzo CA Diabetes Care; 2020 Jan; 43(1):90-97. PubMed ID: 31601640 [TBL] [Abstract][Full Text] [Related]
11. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series. Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418 [TBL] [Abstract][Full Text] [Related]
12. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression. Musso G; Sircana A; Saba F; Cassader M; Gambino R PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368 [TBL] [Abstract][Full Text] [Related]
13. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor. Andrews TJ; Cox RD; Parker C; Kolb J J Emerg Med; 2017 Feb; 52(2):223-226. PubMed ID: 27717592 [TBL] [Abstract][Full Text] [Related]
14. Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol. Rendell MS Diabetes Obes Metab; 2019 Oct; 21(10):2189-2191. PubMed ID: 31334593 [TBL] [Abstract][Full Text] [Related]
15. Cardiac arrest from acute myocardial infarction complicated with sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis. Dai Z; Nishihata Y; Kawamatsu N; Komatsu I; Mizuno A; Shimizu M; Toya N; Ishimatsu S; Komiyama N J Cardiol Cases; 2017 Feb; 15(2):56-60. PubMed ID: 30546697 [TBL] [Abstract][Full Text] [Related]
16. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care. Danne T; Biester T; Kordonouri O Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741 [TBL] [Abstract][Full Text] [Related]
17. SGLT2-I in the Hospital Setting: Diabetic Ketoacidosis and Other Benefits and Concerns. Levine JA; Karam SL; Aleppo G Curr Diab Rep; 2017 Jul; 17(7):54. PubMed ID: 28597228 [TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study. Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427 [TBL] [Abstract][Full Text] [Related]
19. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors. Fleming N; Hamblin PS; Story D; Ekinci EI J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32302001 [TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Fadini GP; Bonora BM; Avogaro A Diabetologia; 2017 Aug; 60(8):1385-1389. PubMed ID: 28500396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]